Oxytocin and Fetal Heart Rate Changes
Launched by UNYIME ITUK · Jul 25, 2017
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how adjusting the amount of a medication called oxytocin could affect the heart rate of a baby during labor. When women receive pain relief through a method called neuraxial analgesia (like an epidural), there can sometimes be concerns about the baby's heart rate. Researchers believe that by reducing the oxytocin infusion rate by half before starting this pain relief, they might be able to lower the chances of the baby experiencing abnormal heart rate changes.
To participate in this trial, women must be healthy, at least 37 weeks pregnant with a single baby, and planning to use neuraxial analgesia for pain relief during labor. They should also be receiving oxytocin to help with labor. However, women who take certain pain medications regularly, have had specific types of labor pain relief already, or have other complications may not be eligible. If you choose to participate, you can expect to help researchers understand better ways to support healthy outcomes for both mothers and babies during labor.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy nulliparous or multiparous women at term (37 \> weeks' gestation)
- • Singleton pregnancy
- • Request for neuraxial analgesia
- • Oxytocin used for induction of labor or augmentation of labor per institutional protocols
- Exclusion Criteria:
- • Use of chronic analgesic medications
- • Prior administration of systemic opioid labor analgesia
- • Non-vertex presentation
- • Contraindication to neuraxial analgesia
- • Category 3 fetal heart rate tracing prior to the initiation of combined spinal epidural analgesia
About Unyime Ituk
Unyime Ituk is a pioneering clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. Committed to enhancing patient outcomes, Unyime Ituk collaborates with leading medical institutions and research organizations to conduct high-quality clinical trials across various therapeutic areas. With a focus on ethical practices and regulatory compliance, the organization strives to bridge the gap between scientific discovery and clinical application, ensuring that groundbreaking therapies are accessible to those in need. Through its unwavering dedication to excellence, Unyime Ituk is at the forefront of transforming the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Iowa City, Iowa, United States
Patients applied
Trial Officials
Unyime Ituk
Study Director
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials